Blog Band - Page 281 of 299

22

Life sciences companies are gearing up to enter new markets as they look to secure their positions after a spate of M&A- licensing- and research partnerships in 2020 Artios partnered…

21

Jan 2021

EVENTS

Exclusive Coverage: Key Takeaways from the Webinar on HEOR/ HTA – The Evolving Role in the Indian Healthcare Ecosystem

Intellimed Healthcare Solutions organized an online webinar on 'Health Economics and Outcomes Research/ Health Technology Assessment: The evolving role in the Indian Healthcare Ecosystem' on 15th January 2021. The objective was to…

21

Jan 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2020

The US FDA has approved 7 NDAs and 2 BLA in Dec 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and…

19

Jan 2021

VIEWPOINTS

PharmaShots Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

In a recent interview with PharmaShots, Jonas Duss, US CEO and Co-Founder at Kaia Health shared his views on the Kaia Health's COPD Pulmonary Rehabilitation App and their collaboration with…

15

Jan 2021

VIEWPOINTS

PharmaShots Interview: Vigeo Therapeutics’ Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020

In a recent interview with PharmaShots, Dr. Jing Watnick, Co-Founder and Chief Executive Officer, and Dr. Lou Vaickus, Interim Chief Medical Officer at Vigeo shared their views on the data findings presented…

14

Jan 2021

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2020

The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter Multiple companies received regulatory…

13

Jan 2021

VIEWPOINTS

PharmaShots Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

In a recent interview with PharmaShots, Kiran Patel, Vice President Clinical Development, Solid Tumor Franchise at Janssen shared his views on the regulatory submission of Amivantamab for the Treatment of Patients with…

13

Jan 2021

EVENTS

Exclusive Webinar: Health Economics & Outcomes Research /Health Technology Assessment: The evolving role in the Indian Healthcare Ecosystem

Shots: Intellimed in collaboration with alpha MD & IMPA along with PharmaShots as the media partner is gladly organizing a webinar on 'Health Economics & Outcomes Research /Health Technology Assessment:…

11

Jan 2021

VIEWPOINTS

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020

In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen's commitment to advance research in rheumatic disease. Shots: Janssen presented clinical trial…

07

Jan 2021

TOP 20

Top 20 Biopharma M&A of 2020 by Total Deal Value

Biopharma merger and acquisition activity in 2020 was mainly filled with late-stage- bolt-on acquisitions- which were orders of magnitude smaller than the mega M&A deals of prior years. AstraZeneca holds…

Top 20 Life Sciences Deals of 2020 by Total Deal Value

Exclusive Coverage: Key Takeaways from the Webinar on HEOR/ HTA – The Evolving Role in the Indian Healthcare Ecosystem

Insights+: The US FDA New Drug Approvals in December 2020

PharmaShots Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

PharmaShots Interview: Vigeo Therapeutics’ Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020

PharmaShots’ Key Highlights of Fourth Quarter 2020

PharmaShots Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC

Exclusive Webinar: Health Economics & Outcomes Research /Health Technology Assessment: The evolving role in the Indian Healthcare Ecosystem

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020

Top 20 Biopharma M&A of 2020 by Total Deal Value

Contact US

OUR INFORMATION

FOLLOW US